Skip to main content
Premium Trial:

Request an Annual Quote

NeoGenomics Immuno-Oncology Profiling Tests

NeoGenomics has launched an expansion of its NeoTYPE cancer profiles to include Tumor Mutation Burden (TMB) and microsatellite instability (MSI) testing. TMB is a new genomic biomarker that is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. The TMB tests will be available on a standalone basis, and in combination with the various cancer-specific NewTYPE tests, the company said. MSI testing will be offered to patients to identify metastatic solid tumors that are MSI-high or mismatch repair deficient (MMR). They company is offering MSI testing as a result of the FDA's recent approval of Merck's Keytruda drug to treat patients identified to have MSI-high or MMR tumors.

The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.